Enter your numbers to estimate your chance of a cardiovascular event over the next 10 years. Then see what that percentage means under the 2026 cholesterol guideline.
Designed mainly for adults 30–79 without known cardiovascular disease or subclinical atherosclerosis, with LDL-C 70–189 mg/dL. Other clinical groups need different decision pathways.
This tool implements the AHA's actual published PREVENT-ASCVD base equation — the same sex-specific logistic model, with the same age, cholesterol, blood pressure, kidney, and metabolic terms (including the interaction and treatment-adjustment terms) used in the official calculator. Values outside the model's validated ranges (age 30–79, total cholesterol 130–320 mg/dL, HDL 20–100 mg/dL, SBP 90–200 mmHg, BMI 18.5–40, eGFR 15–140) are capped to the nearest valid boundary before calculating, which is standard clinical practice for this model.
The output was checked against two independent test cases published by the equation's developers and reproduced them to four decimal places, so the math itself is the real thing. What it can't replace is a clinician who knows your full history, your labs beyond what's asked here, and factors like family history, Lp(a), or coronary calcium that refine risk further under the CPR framework in the 2026 guideline.
Lifestyle remains the primary recommendation. Statins aren't generally indicated on risk grounds alone at this level.
Lipid-lowering therapy can be considered, especially with risk-enhancing factors like family history, elevated Lp(a), or metabolic syndrome.
Lipid-lowering therapy should generally be considered after a clinician discussion of risks and benefits.
At least a moderate-intensity statin is typically recommended; high-risk profiles often warrant high-intensity therapy.